<DOC>
	<DOCNO>NCT00191672</DOCNO>
	<brief_summary>The combination docetaxel gemcitabine show significant activity patient metastatic breast cancer . Several study activity patient multiple line therapy , include patient treat prior taxane therapy . Overall response range 30 % 79 % . The major side effect combination chemotherapy neutropenia , anemia , asthenia , neuropathy , nausea , mucositis , neutropenic fever</brief_summary>
	<brief_title>A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Advanced metastatic breast cancer Disease measure physician radiologic test . May one chemotherapy treatment advance metastatic disease . Patients may receive prior adjuvant chemotherapy , include taxane containing regimen , provide treatment complete least 6 month prior enrollment . Patients may receive prior hormone therapy immunotherapy . Patients nonmeasurable disease Cancer spread brain A patient receive taxane metastatic disease . Pregnancy Patients receive prior gemcitabine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>